5-Jun-2026
Top Krystal Biotech Executives Quietly Unload Major Blocks of Stock
TipRanks (Fri, 5-Jun 10:09 PM ET)
Mid-cap companies with strong growth at modest valuations
Seeking Alpha News (Fri, 5-Jun 6:36 AM ET)
Draft FDA guidance could be a boon for gene therapy developers
Seeking Alpha News (Tue, 2-Jun 1:50 PM ET)
Globe Newswire (Thu, 21-May 8:00 AM ET)
Globe Newswire (Mon, 18-May 8:00 AM ET)
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
Globe Newswire (Thu, 7-May 8:00 AM ET)
Market Chameleon (Mon, 4-May 5:43 AM ET)
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
Globe Newswire (Mon, 4-May 7:00 AM ET)
Krystal Biotech to Present at Upcoming Scientific Conferences
Globe Newswire (Thu, 30-Apr 8:00 AM ET)
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
Globe Newswire (Tue, 21-Apr 8:00 AM ET)
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Krystal Biotech trades on the NASDAQ stock market under the symbol KRYS.
As of June 5, 2026, KRYS stock price declined to $301.00 with 260,134 million shares trading.
KRYS has a beta of 0.72, meaning it tends to be less sensitive to market movements. KRYS has a correlation of 0.06 to the broad based SPY ETF.
KRYS has a market cap of $8.80 billion. This is considered a Mid Cap stock.
Last quarter Krystal Biotech reported $116 million in Revenue and $1.83 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.40.
In the last 3 years, KRYS traded as high as $319.48 and as low as $93.95.
The top ETF exchange traded funds that KRYS belongs to (by Net Assets): IJR, VTI, IWM, VB, XBI.
KRYS has outperformed the market in the last year with a return of +128.0%, while the SPY ETF gained +25.0%. In the last 3 month period, KRYS beat the market returning +13.6%, while SPY returned +7.9%. However, in the most recent 2 weeks KRYS has underperformed the stock market by returning -1.1%, while SPY returned -0.7%.
KRYS support price is $300.34 and resistance is $315.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KRYS shares will trade within this expected range on the day.